Yifat Steuer - MGC Pharmaceuticals Deputy COO
| MGCLFDelisted Stock | USD 0.21 0.00 0.00% |
Insider
Yifat Steuer is Deputy COO of MGC Pharmaceuticals
| Phone | 61 8 6382 3390 |
| Web | https://mgcpharma.com.au |
MGC Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.4527) % which means that it has lost $0.4527 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (2.1854) %, meaning that it generated substantial loss on money invested by shareholders. MGC Pharmaceuticals' management efficiency ratios could be used to measure how well MGC Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.MGC Pharmaceuticals has accumulated 4.35 M in total debt with debt to equity ratio (D/E) of 0.84, which is about average as compared to similar companies. MGC Pharmaceuticals has a current ratio of 0.82, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist MGC Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, MGC Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like MGC Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for MGC to invest in growth at high rates of return. When we think about MGC Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
MGC Pharmaceuticals Limited, a bio-pharma company, develops and supplies phytomedicines in worldwide. MGC Pharmaceuticals Limited was founded in 2014 and is based in West Perth, Australia. Mgc Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. MGC Pharmaceuticals [MGCLF] is traded as part of a regulated electronic over-the-counter service offered by the NASD. Management Performance
| Return On Equity | -2.19 | |||
| Return On Asset | -0.45 |
MGC Pharmaceuticals Leadership Team
Elected by the shareholders, the MGC Pharmaceuticals' board of directors comprises two types of representatives: MGC Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of MGC. The board's role is to monitor MGC Pharmaceuticals' management team and ensure that shareholders' interests are well served. MGC Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, MGC Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Yifat Steuer, Deputy COO | ||
| Robert Clements, Chief Officer | ||
| AngelaMarie Graham, Group Officer | ||
| Roby Zomer, CEO, Executive Director | ||
| Yair Tal, Chief Officer | ||
| Sasha Friedman, Deputy CEO | ||
| Sabina Suljakovic, Head Department | ||
| Amir Polak, Chief Officer | ||
| Nadya Lisovoder, Chief Officer | ||
| Nicole Godresse, Global Officer |
MGC Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is MGC Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.19 | |||
| Return On Asset | -0.45 | |||
| Operating Margin | (3.28) % | |||
| Current Valuation | 24.97 M | |||
| Shares Outstanding | 2.87 B | |||
| Shares Owned By Insiders | 9.10 % | |||
| Shares Owned By Institutions | 6.12 % | |||
| Price To Book | 5.69 X | |||
| Price To Sales | 5.81 X | |||
| Revenue | 4.65 M |
Currently Active Assets on Macroaxis
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Other Consideration for investing in MGC OTC Stock
If you are still planning to invest in MGC Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the MGC Pharmaceuticals' history and understand the potential risks before investing.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |